Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests

Neuroscience Letters

Volumn 546, Issue , 2013, Pages 6-10

  Andreasen, Jesper T ^a   Gynther, Mikko ^b   Rygaard, Allan ^a   Bøgelund, Trine ^a   Nielsen, Simon D ^a   Clausen, Rasmus P ^a   Mogensen, Jesper ^a   Pickering, Darryl S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

AMPA receptor potentiator; Depression; Glutamate; Mouse forced swim test; Mouse tail suspension test; NMDA receptor antagonist

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR AGONIST; CITALOPRAM; DIZOCILPINE; ESCITALOPRAM; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N,N [2,20 (BIPHENYL 4 40 DIYL)BIS(PROPANE 2,1 DIYL)]DIMETHANESULFONAMIDE; NICOTINE TARTRATE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DEPRESSION; DRUG UPTAKE; EQUILIBRIUM DIALYSIS; FEMALE; FORCED SWIMMING TEST; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; DEPRESSION; EXCITATORY AMINO ACID AGONISTS; FEMALE; GLUTAMIC ACID; HINDLIMB SUSPENSION; MICE; NEUROTRANSMITTER AGENTS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SWIMMING; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; UP-REGULATION;

EID: 84878916836     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.04.045     Document Type: Article

References (42)

1. Andreasen J.T., Olsen G.M., Wiborg O., Redrobe J.P. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists but not agonists, in the mouse forced swim and mouse tail suspension tests. J. Psychopharmacol. (Oxf.) 2009, 23:797-804.
2. Andreasen J.T., Redrobe J.P. Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav. Pharmacol. 2009, 20:286-295.
3. Andreasen J.T., Redrobe J.P. Nicotine but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. Behav. Brain Res. 2009, 197:150-156.
4. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra- and interstrain differences in models of behavioral despair. Pharmacol. biochem. behav. 2001, 70:187-192.
5. Barbon A., Caracciolo L., Orlandi C., Musazzi L., Mallei A., La Via L., Bonini D., Mora C., Tardito D., Gennarelli M., Racagni G., Popoli M., Barlati S. Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem. Int. 2011, 59:896-905.
6. Chourbaji S., Vogt M.A., Fumagalli F., Sohr R., Frasca A., Brandwein C., Hortnagl H., Riva M.A., Sprengel R., Gass P. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J. 2008, 22:3129-3134.
7. Cryan J.F., Page M.E., Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl.) 2005, 182:335-344.
8. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213:93-118.
9. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
10. Farley S., Apazoglou K., Witkin J.M., Giros B., Tzavara E.T. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int. J. Neuropsychopharmacol. 2010, 13:1207-1218.
11. Ghasemi M., Montaser-Kouhsari L., Shafaroodi H., Nezami B.G., Ebrahimi F., Dehpour A.R. NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology (Berl.) 2009, 206:325-333.
12. Ghasemi M., Raza M., Dehpour A.R. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J. Psychopharmacol. (Oxf.) 2010, 24:585-594.
13. Goddard A.W., Ball S.G., Martinez J., Robinson M.J., Yang C.R., Russell J.M., Shekhar A. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress. Anxiety 2010, 27:339-350.
14. Gould T.D., O'Donnell K.C., Dow E.R., Du J., Chen G., Manji H.K. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 2008, 54:577-587.
15. Gynther M., Jalkanen A., Lehtonen M., Forsberg M., Laine K., Ropponen J., Leppanen J., Knuuti J., Rautio J. Brain uptake of ketoprofen-lysine prodrug in rats. Int. J. Pharm. 2010, 399:121-128.
16. Hashimoto K. The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1558-1568.
17. Jacobson L.H., Cryan J.F. Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav. Genet. 2007, 37:171-213.
18. Kasper S., McEwen B.S. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008, 22:15-26.
19. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav. Brain Res. 2011, 224:107-111.
20. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
21. Kulkarni S.K., Dhir A. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1248-1254.
22. Kaae B.H., Harpsoe K., Kastrup J.S., Sanz A.C., Pickering D.S., Metzler B., Clausen R.P., Gajhede M., Sauerberg P., Liljefors T., Madsen U. Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites. Chem. Biol. 2007, 14:1294-1303.
23. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033.
24. Li X., Witkin J.M., Need A.B., Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell. Mol. Neurobiol. 2003, 23:419-430.
25. Liu J., Moghaddam B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J. Pharmacol. Exp. Ther. 1995, 274:1209-1215.
26. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
27. Mala H., Chen Y., Worm V.H., Kure J., Kaae B.H., Madsen U., Badolo L., Pickering D.S., Mogensen J. Cognitive enhancing effects of an AMPA receptor positive modulator on place learning in mice. Behav. Brain Res. 2012, 226:18-25.
28. Martinez-Turrillas R., Frechilla D., Del Rio J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 2002, 43:1230-1237.
29. Mayer A., Szasz B.K., Kiss J.P. Inhibitory effect of antidepressants on the NMDA-evoked [(3)H]noradrenaline release from rat hippocampal slices. Neurochem. Int. 2009, 55:383-388.
30. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995, 269:1692-1696.
31. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17:2921-2927.
32. Murakami H., Takanaga H., Matsuo H., Ohtani H., Sawada Y. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H1022-H1028.
33. Murrough J.W. Ketamine as a novel antidepressant: from synapse to behavior. Clin. Pharmacol. Ther. 2012, 91:303-309.
34. Pruus K., Rudissaar R., Allikmets L., Harro J. The effect of the NMDA receptor antagonist dizocilpine on behavioral manifestations of serotonin and adrenergic antidepressants in rats. Methods Find. Exp. Clin. Pharmacol. 2010, 32:123-128.
35. Renard C.E., Dailly E., David D.J., Hascoet M., Bourin M. Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam. Clin. Pharmacol. 2003, 17:449-455.
36. Rosenzweig-Lipson S., Beyer C.E., Hughes Z.A., Khawaja X., Rajarao S.J., Malberg J.E., Rahman Z., Ring R.H., Schechter L.E. Differentiating antidepressants of the future: efficacy and safety. Pharmacol. Ther. 2007, 113:134-153.
37. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
38. Schilstrom B., Fagerquist M.V., Zhang X., Hertel P., Panagis G., Nomikos G.G., Svensson T.H. Putative role of presynaptic alpha7* nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 2000, 38:375-383.
39. Schober D.A., Gill M.B., Yu H., Gernert D.L., Jeffries M.W., Ornstein P.L., Kato A.S., Felder C.C., Bredt D.S. Transmembrane AMPA receptor regulatory proteins and cornichon-2 allosterically regulate AMPA receptor antagonists and potentiators. J. Biol. Chem. 2011, 286:13134-13142.
40. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996, 29:23-26.
41. Svenningsson P., Bateup H., Qi H., Takamiya K., Huganir R.L., Spedding M., Roth B.L., McEwen B.S., Greengard P. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur. J. Neurosci. 2007, 26:3509-3517.
42. Tizabi Y., Bhatti B.H., Manaye K.F., Das J.R., Akinfiresoye L. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience 2012, 213:72-80.